Breaking News

Aldevron, Ginkgo Bioworks Partner on mRNA Vax Mfg. Breakthrough

Achieved improvements in manufacturing yield of vaccinia capping enzyme (VCE), a component often required to produce mRNA therapies and vaccines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Aldevron, a research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, and Ginkgo Bioworks, Inc., announced a manufacturing breakthrough leveraging their strategic partnership.   Aldevron manufactures high-quality components in the field of genetic medicine and Ginkgo is building a platform for cell programming aimed at enabling customers to improve products and manufacturing processes for greater efficiency and sustainability.   The companies have been working together to optimize ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters